evaluate the food technology company chinova bioworks on glp-1 diet Drugs Are Rewriting Rules of Food companies are targeting users

New FDA policy on compounding GLP-1 drugs New FDA policy on compounding GLP-1 drugs On April 24, 2025, FDA announced that licensed pharmacies and physicians can no longer compound semaglutide (a GLP-1 drug used in Ozempic & Wegovy) and outsourcing facilities must stop production by May 22, 2025

There was no clinically significant correlation between change in GLP-1 and change in bodyweight

Available pack sizes 14s, 30s

Mergoni G, Ergun S, Vescovi P, Mete O, Tanyeri H, Meleti M

Potential Downsides and Unknowns Long-term safety : Retatrutide is still in trials, so long-term LDL and cardiovascular outcomes arent confirmed